All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.
Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.
Researchers from Central Drug Research Institute (CDRI) and the Academy of Scientific & Innovative Research (AcSIR) have synthesized and evaluated a series of novel antileishmanial agents. Synthesis and optimization of a series of halogen-rich salicylanilides led to the discovery of compounds [I] and [II], which demonstrated the best antileishmanial activity, with IC50 values of 2.89 μM and 2.09 μM, respectively against Leishmania donovani amastigote.
Tonix Pharmaceuticals Holding Corp. has announced it plans to develop the TNX-3900 series of oral antivirals as monotherapy or in combination with other antivirals, following an agreement whereby it has acquired all of the assets of Healion Bio Inc., including its entire portfolio of next-generation antiviral technology assets.
Xinthera Inc. has divulged pyridinones acting as MAP kinase-activated protein kinase 2 (MAPKAPK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, metabolic diseases, inflammation and cardiovascular and cerebrovascular disorders.
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness which in many ways goes against the mainstream health care state of mind about obesity.
Outcomes after therapy with DNA-damaging agents such as irinotecan or oxaliplatin have been seen to improve in patients with homologous recombination-deficient colorectal cancer (HRD CRC) compared to those who have HR proficient CRC (HRP CRC).
Genetically modified derivatives of the chimeric oncolytic virus (OV) CF33 have previously shown cancer selectivity and oncolytic potency against various solid tumors.
Upregulation of C-X-C motif chemokine ligand 1 (CXCL1) has been validated in patients with colorectal cancer (CRC), but the mechanism behind CXCL1 affecting CRC tumor cell progression is not clear. Gene-editing techniques were used to investigate the impact of CXCL1 knockout and overexpression in...
Previous studies have demonstrated that increased expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) correlated with poor prognosis in patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC). In the current study, a research team at the University...
Several studies on the effect of hyperglycemia on malignant tumor progression have been performed; hyperglycemia is known to be a risk factor for breast cancer-related mortality, since it causes aberrant gene expression by altering the epigenome (hyperglycemic memory).
Greenlight Biosciences Holdings PBC has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a first-in-human phase I/II trial of its mRNA vaccine candidate against COVID-19, GLB-COV2-043, as a booster for previously vaccinated individuals.
Herophilus Inc. is conducting in vivo studies of lead candidate HRP-12975, a small-molecule therapy for Rett syndrome, with funding from the Rett Syndrome Research Trust. The company is generating efficacy and safety data with HRP-12975 using genetic mouse models of Rett syndrome.
Lapix Therapeutics Inc. has announced the successful outcome of its pre-IND meeting request with the FDA to achieve alignment on the company's IND-enabling plan for LPX-TI641, being developed for neuro-autoimmune indications such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders...
Inmune Bio Inc., together with a collaborator at University of California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a dominant-negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Duchenne muscular dystrophy (DMD) and showed a...
Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease, and it is pathologically related with frontotemporal dementia (FTD). Genetic studies have identified C9ORF72 as a major genetic cause of ALS/FTD. Further genetic analyses and validation studies have...
Researchers at Indiana University School of Medicine are exploring avenues to heal wounds by identifying proteins that are active in fetuses, but largely inactive in adults and absent in diabetic adults. They have identified a protein called nonselenocysteine-containing phospholipid hydroperoxide...
Cells that break away from a tumor and colonize other regions of the body express genes that are different from those of the cancer from which they originate. Now, a Baylor College of Medicine study has found that metastases can be classified into four cancer subtypes regardless of the primary...
Androgen deprivation therapy (ADT) is still the main treatment option for locally advanced and metastatic prostate cancer (PCa); however, most patients receiving ADT develop resistance to treatment and relapse, with a more aggressive form of cancer, castration-resistant prostate cancer (CRPC).
Heart failure still remains a leading cause of death worldwide. Improving risk stratification and prognostic analysis tools is required to aid in the management of the disease.
Rise Therapeutics LLC has received FDA clearance for its IND application to proceed with a phase I trial of R-3750, a synthetic biology-based cellular immunotherapy being developed for the treatment of inflammatory bowel disease. The phase I trial...
Hepatocellular death is an important process for liver homoeostasis by elimination and replacement of impaired hepatocytes. Hepatocellular death occurs little under normal conditions in the healthy liver, and it plays a key role as a trigger of...
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Exegi Pharma LLC has received FDA clearance of its IND application for EXE-346, allowing the company to initiate a clinical trial to evaluate EXE-346 in the management of excessive stool frequency in patients with an ileal pouch-anal anastomosis...
Researchers from University Medical Center Utrecht and Yale University School of Medicine have recently described two novel, strictly anaerobic Allobaculum strains, 128T and 539T, isolated from the feces of humans with inflammatory bowel disease...
Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis,...
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.